FDA
-
-
-
-
-
-
-
Egalet Reports First Quarter 2018 Financial Results
-
-
-
-
-
-
-
Egalet (EGLT) Reports Issuance of New U.S. Patent for Guardian Technology
-
-
-
-
-
-
-
Egalet (EGLT) Announced New Data at PAINWEEK Demonstrating Potential of ARYMO ER to Deter Opioid Abuse
-
-
-
-
-
-
-
Egalet Receives Complete Response Letter from U.S. Food and Drug Administration for Prior Approval Supplement for 10 mg and 15 mg Dosage Strengths of OXAYDO
-
-
-
-
-
-
-
Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™
-
-
-
-
-
-
-
Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain
-
251,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All